Oral News and Research

RSS

Turmeric for psoriasis performs no better than placebo

Anecdotal evidence touting the healing power of the Indian spice turmeric for psoriasis received a setback in a prospective study published this month by a leading dermatology journal stating that the low response rate of patients who ingested the active ingredient of the exotic spice was probably a result of the placebo effect.

1 Mar 2008

New guidelines for von Willebrand disease

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, has issued the first clinical guidelines in the United States for the diagnosis and management of von Willebrand Disease (VWD), the most common inherited bleeding disorder.

1 Mar 2008

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection (olanzapine LAI) for the treatment and maintenance treatment of schizophrenia in adults, the company announced.

28 Feb 2008

Galderma to acquire CollaGenex Pharmaceuticals

Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, and CollaGenex Pharmaceuticals, Inc. has announced a definitive agreement pursuant to which Galderma's U.S. holding company, Galderma Laboratories, Inc., will acquire all of the outstanding shares of CollaGenex at a price of $16.60 per share in cash, representing approximately $420 million for the equity of CollaGenex.

27 Feb 2008

Tenofovir gel safe for daily use over an extended period

A vaginal microbicide that incorporates an antiretroviral (ARV) drug normally used to treat people with HIV is safe for sexually active HIV-negative women to use every day over an extended period, suggest results of a clinical trial of tenofovir topical gel.

27 Feb 2008

Extract of broccoli sprouts may protect against bladder cancer

A concentrated extract of freeze dried broccoli sprouts cut development of bladder tumors in an animal model by more than half, according to a report in the March 1 issue of Cancer Research, a journal of the American Association for Cancer Research.

26 Feb 2008

High zinc status in lung cells slows growth and induces DNA

Researchers at the University of Maryland at College Park have discovered that Normal Human Bronchial Epithelial (NHBE) cells cultured in medium with elevated zinc level, at the high end of plasma zinc attainable by oral supplementation, demonstrated inhibition of cell growth, up-regulation of growth arrest and DNA damage-induced gene (Gadd45) mRNA and protein expression, and blockage of G2/M cell cycle progression.

26 Feb 2008

New gene discovered that determines hair texture and density in humans

A Columbia University Medical Center research team has discovered a new gene involved in determining hair texture in humans.

26 Feb 2008

Quality of care for inflammatory bowel disease patients can be improved

Inflammatory bowel disease (IBD) is a chronic recurrent gastrointestinal disease.

26 Feb 2008

Technology to defeat bacterial infections shows positive results

The use of natural controls against serious bacterial infection and superbugs is being led by a UK company. Scientists at Biocontrol Ltd have presented at the Bacteriophage 2008 meeting in Hertfordshire a first look at the results of their initial Phase II clinical trial.

25 Feb 2008

Multiple approaches to type 1 diabetes

Type 1 diabetes, formerly called insulin-dependent diabetes, juvenile diabetes or childhood-onset diabetes, affects 1 to 2 million people in the U.S. and millions more worldwide.

21 Feb 2008

FDA approves XYZAL (levocetirizine dihydrochloride) for allergies and chronic idiopathic urticaria

UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.

20 Feb 2008

CT scan can harm kidneys, but cheap drug can help

As more and more Americans undergo CT scans and other medical imaging scans involving intense X-rays, a new study suggests that many of them should take a pre-scan drug that could protect their kidneys from damage.

20 Feb 2008

Nabilone marijuana-based drug reduces fibromyalgia pain

Patients with fibromyalgia treated with a synthetic form of marijuana, nabilone, showed significant reductions in pain and anxiety in a first-of-its-kind study, published in The Journal of Pain.

17 Feb 2008

Discovery of previously unknown mechanism that leads to cleft palate

By creating a genetic mutation in zebrafish, University of Oregon scientists say they've discovered a previously unknown mechanism for cleft palate, a common birth defect in humans that has challenged medical professionals for centuries.

12 Feb 2008

Alpha-linolenic acid good for dry eye syndrome

Research conducted by Massachusetts Eye and Ear Infirmary (MEEI) Cornea Service Director and Harvard Medical School Professor Reza Dana, M.D., M. Sc., MPH, and colleagues at the Schepens Eye Research Institute have found for the first time that topical drop application of alpha-linolenic acid (ALA) led to a significant decrease in clinical signs of dry eye syndrome (DES) in animal models.

12 Feb 2008

$1-year results of bronchial thermoplasty in refractory asthma$

1-year results of bronchial thermoplasty in refractory asthma

Asthmatx, Inc. has announced the publication of data from the Research in Severe Asthma (RISA) Trial of bronchial thermoplasty in the American Journal of Respiratory and Critical Care Medicine (AJRCCM, 2007; 176:1185-1191).

12 Feb 2008

Experimental drug shows promise for cystic fibrosis

An experimental drug that has proven effective in treating muscular dystrophy also works for cystic fibrosis, according to researchers at the University of Alabama at Birmingham (UAB).

5 Feb 2008

Study suggests Risperidone long-acting injection combined with standard treatment helped delay time to relapse in patients with bipolar disorder

Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study compared patients who received RLAI and standard treatment to those who received standard treatment combined with placebo.

4 Feb 2008

Reducing pain could lead to increased immunization rates

Studies have shown that some parents are reluctant to have their children immunized because they fear their children will experience significant pain during and after the injections.

4 Feb 2008